Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and Cerus (NASDAQ:CERS – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Longview Acquisition Corp. II and Cerus, as reported by MarketBeat.

Get Longview Acquisition Corp. II alerts:

Cerus has a consensus target price of $4.88, suggesting a potential upside of 61.96%. Given Cerus' higher probable upside, analysts plainly believe Cerus is more favorable than Longview Acquisition Corp. II.

Institutional and Insider Ownership

66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. Comparatively, 82.5% of Cerus shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 7.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Longview Acquisition Corp. II and Cerus' top-line revenue, earnings per share (EPS) and valuation.

Longview Acquisition Corp. II has higher earnings, but lower revenue than Cerus.

Risk & Volatility

Longview Acquisition Corp. II has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Longview Acquisition Corp. II and Cerus' net margins, return on equity and return on assets.

Summary

Cerus beats Longview Acquisition Corp. II on 6 of the 10 factors compared between the two stocks.

About Longview Acquisition Corp. II

(Get Rating)

Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.

About Cerus

(Get Rating)

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.